Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Possis to start cerebrovascular stroke trial:

This article was originally published in Clinica

Executive Summary

Possis Medical has received approval from the FDA to begin US clinical trials of its clot-busting AngioJet system in the treatment of severe acute cerebrovascular stroke. The Phase I trial will enrol 30 patients at six hospitals, said the Minneapolis, Minnesota-based company. The AngioJet device is already approved in the US for removing blood clots in coronary arteries and bypass grafts and is currently being assessed as a treatment for carotid stroke (see Clinica No 844, p 16).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel